
Thuja et al. invest €2.4m in Therasolve
Thuja Capital has taken part in a €2.4m series-A funding round for Therasolve, a Belgian developer of medical devices.
Thuja is an existing investor in the company alongside LRM, a Limburg-focused investment company. The two firms first invested in Therasolve in August 2011.
Thuja and LRM were joined in the round by Ark Angels Activator Fund and Business Angels of BAN Vlaanderen, which are collectively supplying €900,000 towards the round.
Therasolve will use the fresh capital to aid in the development and commercialisation of its MemoPatch product.
Company
Founded in 2009 and headquartered in Diepenbeek, Therasolve is a developer of medical skin patches. The company has developed the MemoPatch, which is designed to remind patients to take their medication on time.
People
Wim De Geest is the CEO of Therasolve. Thuja managing partner Harrold van Barlingen is chairman of the company's board. LRM investment manager Debora Dumont sits on the board.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater